Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal (groups a, c, y and w-135) polysaccharide diphtheria toxoid conjugate vaccine (Sanofi, 043ed3)
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Polysaccharide diphtheria conjugate vaccine, marketed under the brand name Menactra, is a quadrivalent meningococcal conjugate vaccine developed by Sanofi Pasteur. It is composed of capsular polysaccharides from Neisseria meningitidis serogroups A, C, Y, and W-135, each individually conjugated to a diphtheria toxoid protein carrier. This conjugation converts the immune response from T-cell independent to T-cell dependent, which enables the induction of immunological memory and a more robust antibody response. The vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by N. meningitidis serogroups A, C, Y, and W-135 in individuals aged 9 months through 55 years. It was the first quadrivalent conjugate meningococcal vaccine licensed in the United States, receiving FDA approval in 2005.
- Brand names
- Menactra
- Other names
- MCV4MCV-4MCV 4MenACYW-DTquadrivalent meningococcal conjugate vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal (groups a, c, y and w-135) polysaccharide diphtheria toxoid conjugate vaccine (Sanofi, 043ed3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal (groups a, c, y and w-135) polysaccharide diphtheria toxoid conjugate vaccine (Sanofi, 043ed3).